NovoCure (NVCR) Set to Announce Earnings on Thursday

NovoCure (NASDAQ:NVCR - Get Free Report) will release its earnings data before the market opens on Thursday, May 2nd. Analysts expect NovoCure to post earnings of ($0.42) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.08. The firm had revenue of $133.80 million for the quarter, compared to analyst estimates of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative return on equity of 51.63%. NovoCure's quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm posted ($0.36) EPS. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NovoCure Price Performance

Shares of NASDAQ NVCR traded down $0.11 during trading on Thursday, hitting $12.23. 1,152,123 shares of the company were exchanged, compared to its average volume of 1,344,545. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -6.27 and a beta of 0.42. The company has a debt-to-equity ratio of 1.57, a current ratio of 5.78 and a quick ratio of 5.56. NovoCure has a 1 year low of $10.87 and a 1 year high of $83.60. The firm's fifty day moving average price is $14.49 and its 200 day moving average price is $13.92.

Insider Activity at NovoCure

In other NovoCure news, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $16.03, for a total value of $33,775.21. Following the sale, the chief operating officer now directly owns 252,452 shares of the company's stock, valued at $4,046,805.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Frank X. Leonard sold 1,679 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $16.03, for a total value of $26,914.37. Following the completion of the transaction, the executive vice president now owns 160,938 shares of the company's stock, valued at $2,579,836.14. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $16.03, for a total value of $33,775.21. Following the completion of the transaction, the chief operating officer now directly owns 252,452 shares of the company's stock, valued at approximately $4,046,805.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,921 shares of company stock valued at $127,161. Corporate insiders own 5.67% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on NVCR. Piper Sandler reaffirmed an "overweight" rating and set a $28.00 price target (up previously from $25.00) on shares of NovoCure in a research note on Wednesday, April 10th. Wells Fargo & Company dropped their price objective on shares of NovoCure from $49.00 to $42.00 and set an "overweight" rating for the company in a research note on Wednesday, April 3rd. Evercore ISI upped their price objective on shares of NovoCure from $14.00 to $15.00 and gave the company an "in-line" rating in a research note on Friday, February 23rd. Wedbush reiterated a "neutral" rating and set a $21.00 target price on shares of NovoCure in a report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. upped their price target on NovoCure from $15.00 to $17.00 and gave the stock a "neutral" rating in a report on Tuesday, March 19th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $31.13.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.